Recent studies have reported cardiac abnormalities in patients with coronavirus disease 2019 . 1 Echocardiography remains an essential diagnostic tool in this climate, particularly with emerging data that myocardial injury appears to be associated with adverse prognosis 2 and that echocardiography may add important prognostic information. 3,4 We present our institutional experience with echocardiography in the current pandemic with the goal of assessing the prevalence and reversibility of left ventricular (LV) dysfunction.Requests for echocardiograms in patients with COVID-19 were screened for appropriateness by echocardiography laboratory physicians; all performed studies (n = 125 patients over 49 days, all hospitalized) were included in this report. Studies were performed on standard (EPIQ; Philips Healthcare, Andover, MA), laptop-sized (Vivid I; GE Healthcare, Milwaukee, WI), or tablet (Lumify; Philips Healthcare) machines. Echocardiographic measurements were made according to society guidelines. 5 Echocardiographic data were extracted from the clinical report and clinical information from the medical record.Average patient age was 64 6 15 years, and 50 (40%) were women. The most common comorbidities included hypertension (60%), diabetes mellitus (41%), and obesity (50%; mean body mass index, 31 6 7 kg/m 2 ). The majority (n = 85 [69%]) of patients were in the intensive care unit at time of echocardiography, with 75 (88%) requiring mechanical ventilation and 60 (71%) vasopressor support.

When performed at the time of outpatient echocardiography, LUS findings of pulmonary congestion differ between patients with known HF and those with hypertension, and may be associated with adverse outcomes.

No abstract

No abstract

No abstract